ARIAD Announces Issuance of Key U.S. Patent on Brigatinib
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- US stock futures steady after tech slump; investors focus on Middle East tensions
ARIAD Pharma (ARIA) Issued Brigatinib-Related U.S. Patent
April 22, 2015 7:36 AM EDTARIAD Pharma (NASDAQ: ARIA) announced the issuance of its first U.S. patent on brigatinib, ARIADs investigational ALK inhibitor. The United States Patent and Trademark Office granted U.S. Patent No. 9,012,462 under the title, Phosphorous Derivatives as Kinase Inhibitors. The patent provides composition-of-matter protection... More
